

**TYPE 3 DIABETES: THE MOLECULAR LINK BETWEEN  
INSULIN RESISTANCE AND NEURODEGENERATION****Temirova Bakhora Khakim qizi***Faculty: Pediatrics, Group: 219  
khakimovna1103@gmail.com***Kenjaboyeva Sevinch Uktamboyevna***Faculty: General Medicine – 2,  
3rd Year, Group: 306  
skenjaboyeva3@gmail.com***Odilova Nigora Foziljon qizi***Faculty: Pediatrics, Group: 211  
nigoraodilova556@gmail.com***Hamdamova Farangiz Baxtiyor qizi***Faculty: General Medicine – 1, Group: 232  
xamdamovafarangiz6@gmail.com***Karimova Nargiza Erkinovna***Faculty: Dentistry, Group: 203  
karimovanargiza880@gmail.com  
Samarkand State Medical University,  
Samarkand, Uzbekistan***Abstract**

Type 3 diabetes (T3D) is a proposed term for Alzheimer's Disease (AD) that represents a form of diabetes that selectively involves the brain. This condition is characterized by brain-specific insulin resistance and insulin deficiency, which triggers a cascade of neurodegenerative processes. This review explores the pathophysiology, clinical presentation, and emerging therapeutic landscape for T3D.

**Keywords:** *Type 3 diabetes, Alzheimer's disease, brain insulin resistance, amyloid-beta, tau pathology, neurodegeneration, intranasal insulin*

**Introduction**

The concept of "Type 3 diabetes" emerged from the discovery that the brain is an insulin-sensitive organ and that impaired insulin signaling within the central nervous system (CNS) contributes significantly to cognitive decline (de la Monte and Wands 2008).

While Type 1 diabetes is characterized by an absolute insulin deficiency due to autoimmune destruction of pancreatic beta cells, and Type 2 diabetes (T2D) involves systemic insulin resistance and relative insulin deficiency, Type 3 diabetes is defined by chronic insulin resistance and insulin-like growth factor (IGF) signaling dysfunction

localized within the brain. Though T2D is a major risk factor for AD, T3D can occur in the absence of systemic hyperglycemia, suggesting that the brain can develop metabolic failure independently of the body (Steen et al. 2005).

### Pathophysiology

The pathophysiology of Type 3 diabetes is a complex interplay of metabolic failure and proteotoxicity. In the brain, insulin serves as a neuroprotective agent, regulating synaptic plasticity, memory formation, and neuron survival. In Type 3 diabetes, insulin receptors in the hippocampus and cerebral cortex become desensitized, leading to a “starved” state for neurons despite adequate blood glucose availability (Talbot et al. 2012).

A key mechanism involves amyloid-beta ( $A\beta$ ) and tau pathology. Both insulin and  $A\beta$  are degraded by the Insulin-Degrading Enzyme (IDE). Hyperinsulinemia or insulin resistance diverts IDE activity toward insulin, allowing  $A\beta$  to accumulate and form neurotoxic plaques. Impaired insulin signaling also overactivates Glycogen Synthase Kinase 3 $\beta$  (GSK-3 $\beta$ ), causing tau hyperphosphorylation and the formation of neurofibrillary tangles (Craft and Watson 2004).

Chronic insulin resistance additionally triggers mitochondrial dysfunction, generating reactive oxygen species (ROS) and oxidative stress, which damages neuronal membranes and worsens neuroinflammation. Pro-inflammatory cytokines, such as TNF- $\alpha$ , further inhibit insulin signaling, creating a feedback loop that accelerates neuronal apoptosis (de la Monte 2014).

### Clinical Features & Diagnosis

Diagnosis relies on identifying metabolic and degenerative biomarkers. In cerebrospinal fluid (CSF), patients often show reduced levels of insulin alongside increased levels of phosphorylated tau (p-tau) and amyloid-beta 42 ( $A\beta$ 42). Recent research has also highlighted the role of neural-derived extracellular vesicles, or exosomes, in the blood, which provide a non-invasive window into brain insulin resistance (Kapogiannis et al. 2015).

Imaging studies further support the diagnosis. FDG-PET scans typically reveal regional glucose hypometabolism in the parietotemporal cortex, a hallmark feature shared by both Alzheimer’s disease and Type 3 diabetes. MRI findings often demonstrate progressive hippocampal atrophy and widening of the sulci, which correlate with the severity of impaired insulin signaling (Baker et al. 2011).

### Management & Therapeutic Approaches

Pharmacological approaches include metformin, which can cross the blood-brain barrier and may reduce amyloid-beta levels while improving tau pathology through activation of AMPK (Koenig et al. 2017). Glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide, have demonstrated neuroprotective effects in clinical trials by enhancing synaptic plasticity and reducing neuroinflammation (Gejl et al. 2016).

Experimental treatments focus on delivering insulin directly to the central nervous system. Intranasal insulin bypasses the blood-brain barrier, avoiding systemic hypoglycemia, and clinical trials have shown improvements in memory and functional status in patients with mild cognitive impairment and Alzheimer's disease (Craft et al. 2012).

Lifestyle interventions also play a key role. A ketogenic diet provides ketones as an alternative fuel source for insulin-resistant neurons, while physical exercise increases the expression of brain-derived neurotrophic factor (BDNF) and enhances both systemic and central insulin sensitivity (Cercato et al. 2019).

### Conclusion

Type 3 diabetes represents a paradigm shift in our understanding of neurodegeneration. By framing Alzheimer's as a metabolic disorder, the medical community can move toward more integrated diagnostic and therapeutic frameworks. Addressing brain insulin resistance through a combination of intranasal insulin, insulin-sensitizing medications, and metabolic lifestyle changes offers a promising frontier for mitigating the global burden of dementia.

### References

1. Baker, L.D., et al. (2011). "Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism." *Archives of Neurology*, 68(1), 51–57.
2. Cercato, C., et al. (2019). "The role of physical exercise in Type 3 Diabetes." *Frontiers in Endocrinology*, 10, 729.
3. Craft, S., & Watson, G.S. (2004). "Insulin and neurodegeneration." *Lancet Neurology*, 3(3), 169–178.
4. Craft, S., et al. (2012). "Intranasal insulin therapy for Alzheimer disease and amnesic mild cognitive impairment: a pilot clinical trial." *Archives of Neurology*, 69(1), 29–38.
5. de la Monte, S.M. (2014). "Type 3 diabetes is the primary cause of Alzheimer's disease." *Journal of Diabetes Science and Technology*, 8(6), 1185–1192.
6. de la Monte, S.M., & Wands, J.R. (2008). "Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed." *Journal of Diabetes Science and Technology*, 2(6), 1101–1113.
7. Gejl, M., et al. (2016). "In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Cerebral Glucose Metabolism." *Frontiers in Aging Neuroscience*, 8, 108.
8. Kapogiannis, D., et al. (2015). "Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease." *FASEB Journal*, 29(2), 589–596.

9. Koenig, A.M., et al. (2017). “Effects of the Insulin Sensitizer Metformin on AD Biomarkers: A Randomized, Placebo-Controlled Crossover Trial.” *Contemporary Clinical Trials*, 60, 20–23.
10. Steen, E., et al. (2005). “Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes?” *Journal of Alzheimer’s Disease*, 7(1), 63–80.
11. Talbot, K., et al. (2012). “Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.” *Journal of Clinical Investigation*, 122(4), 1316–1338.